诚信认证:
工商注册信息已核实!
![](https://img.antpedia.com/cbook/dist_templates/0/images/icon14.png)
![](https://cbook.antpedia.com/attachments/design/6751/1682393653-0588.jpg)
Laquinimod
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
阿拉丁 | 生产商 | 上海 | 现货 |
货号 | CAS号 | 操作 |
---|---|---|
L126699-250mg | 248281-84-7 | 询底价 |
L126699-50mg | 248281-84-7 | 询底价 |
L126699-1g | 248281-84-7 | 询底价 |
属性
溶解性 | DMSO 61 mg/mL (170.96 mM);Water <1 mg/mL (<1 mM);Ethanol 1 mg/mL (2.8 mM) |
存贮条件 | 储存温度-20°C |
描述
产品介绍 | Laquinimod是有效的免疫调节剂。Phase 3。 |
备注 | Laquinimod is a potent immunomodulator. |
生化机理 |
Laquinimod (ABR-215062) is a potent immunomodulator. Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS). Laquinimod has demonstrated significant activity in suppressing experimental autoimmune encephalomyelitis, an animal model of RRMS. In phase I and II clinical trials, the drug was well tolerated, with some hints of efficacy in small numbers of patients with RRMS. While the mechanism of action of the drug is unknown, it likely involves Th1 to Th2/Th3 immune deviation, promotion of the synthesis and release of neurotrophic factors, and other possible neuroprotective effects. A Phase II study of Laquinimod in active lupus arthritis patients is currently ongoing, if successful, will lead to the approval of the first oral immunomodulatory drug for suppressing multiple sclerosis disease activity. |
别名 | 拉喹莫德;ABR-215062;ABR 215062;ABR215062;5-Chloro-4-hydroxy-1-methyl-2-oxo-N-ethyl-N-phenyl-1,2-dihydroquinoline-3-carboxamide;5-Chloro-N-Et-4-hydroxy-1-methyl-2-oxo-N-Ph-1,2-dihydroquinoline-3-carboxamide |
Laquinimod信息由上海阿拉丁生化科技股份有限公司为您提供,如您想了解更多关于Laquinimod报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途